News Column

Chasesun to Raise CNY950mn onTCM Automated Production Base

August 19, 2014

TIANJIN, August 19, SinoCast -- Tianjin Chasesun Pharmaceutical (300026) intended to raise not more than CNY 950 million through additionally issuing not more than 40 million shares for building an "automated production base of traditional Chinese medicine (TCM)".

The base has a total investment of CNY 990 million, is designed to have annual production capacity of 25 million tons of all kinds of single-flavor TCM particles and 3,000 tons of TCM slices.

In the first half of this year, Chasesun's operating revenue hit CNY 1.248 billion, growing 32.67% over a year earlier. Net profits attributable to shareholders hit CNY 220 million, growing 33.51%; basic earnings per share were CNY 0.39.

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Sinocast Health Care & Medicine Beat (China)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters